Avtal | $24,000,000 | (Mar 20, 2026)
Parallel(FRANCE) | $20,000,000 | (Mar 20, 2026)
Claros | $30,000,000 | (Mar 20, 2026)
VitriVax
United States
- Boulder, Colorado
- 07/12/2023
- Unknown
- $5,000,000
VitriVax is a formulation technology company developing innovative solutions to maximize global accessibility and utility of human and animal vaccines. Our ALTA platform makes vaccines thermostable up to 70°C, and single shot - combining prime and boost doses into one injection.
- Industry Biotechnology Research
- Website https://vitrivaxbio.com/
- LinkedIn https://www.linkedin.com/company/vitrivax/about/
Related People
Romulo ColindresFounder
United States -
Raleigh-Durham-Chapel Hill Area
Strategic and operationally focused pharma executive and business leader with proven track record for building successful teams and developing and executing launch plans to bring innovative products to market. Industry experience in medical affairs, epidemiology/health outcomes, clinical development, market access, regulatory affairs and pharmacovigilance.
Special Interests: healthcare technology, bioinformatics, pediatrics, infectious disease, global/public health, vaccinology, immunology, and entrepreneurship.
Latent | $80,000,000 | (Mar 20, 2026)
Corridor | $25,000,000 | (Mar 20, 2026)
RunSybil | $40,000,000 | (Mar 20, 2026)
PADO AI | $6,000,000 | (Mar 20, 2026)
Edra | $30,000,000 | (Mar 20, 2026)
Chalkie AI | $4,000,000 | (Mar 20, 2026)
Deeptune | $43,000,000 | (Mar 20, 2026)
SetSale | $2,000,000 | (Mar 19, 2026)
Laminar (YC S24) | $3,000,000 | (Mar 19, 2026)